Vivesto AB (STO:VIVE)
Sweden · Delayed Price · Currency is SEK 8.82
-0.12 (-1.34%)
Sep 4, 2026, 5:29 PM CET
Vivesto AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
98.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.61M | 3.57M | 117.50% |
| Dec 31, 2022 | 3.04M | -25.83M | -89.47% |
| Dec 31, 2021 | 28.87M | 24.90M | 626.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Newbury Pharmaceuticals AB | 35.02M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Enorama Pharma AB | 3.26M |
Vivesto AB News
- 22 days ago - Vivesto AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Vivesto AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Vivesto AB Annual report: Q4 2025 - Filings
- 6 months ago - Vivesto AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Vivesto AB Transcript: DNB Carnegie Småbolagsdag - Transcripts
- 9 months ago - Vivesto AB Transcript: Study update - Transcripts
- 9 months ago - Vivesto AB Press release: Study update - Filings
- 9 months ago - Vivesto AB Quarterly report: Q3 2025 - Filings